Stocks held onto modest gains Monday, respecting a skin-tight
range as investors took a breather after Friday's triple-digit
rally in the Dow Jones Industrials followed an upbeat job-market
report. Although some Fed officials tried to warn of increased odds
for an imminent stimulus tapering as a result of November payroll
data, the stock market regained its footing. Today's merger mania
and upbeat Chinese trade data helped make the bull's case.
Some of the Federal Reserve's most hawkish members, speaking
today, suggested that November payroll data is enough ammunition
for the central bank to pare its stimulus program. But given the
performance of both the stock and bond markets in the face of
recent bullish economic data, investors have possibly already
accepted an inevitable tapering, looking instead to challenge
recent record highs.
Here's where the markets stand at the close:
Dow Jones Industrial Index was up 5.33 (0.03%) at 16,025
S&P 500 was up 3.28 (+0.2%) at 1,808.37
Nasdaq Composite Index was up 6.23 (+0.2%) at 4,068.75
FTSE 100 was up 0.11%
Nikkei 225 was up 2.29%
Hang Seng Index was up 0.29%
Shanghai China Composite Index was up 0.05%
HIHO Received three tooling orders designed to produce plastic
components for printers offered by "a leading U.S. printer
SYY Agreed to acquire private food distributor US Foods for
about $3.5 billion excluding debt.
HDSN The EPA has issued a proposed ruling pertaining to the
allowances for virgin production of HCFCs, primarily R-22, for 2015
through 2019. EPA's proposed ruling sets the schedule for the final
stage of the phase out of virgin R-22 production. R-22 is a widely
used refrigerant in the residential and commercial setting, but has
been shown to deplete the ozone layer.
ARRY Reported Monday an updated clinical safety and efficacy
data on ARRY-614 in patients with myelodysplastic syndromes (MDS)
that showed that ARRY-614 was "generally well tolerated" in
lower-risk MDS patients.
CRIS Announced preliminary first-in-human results from its
ongoing Phase 1 trial of CUDC-907 demonstrating preliminary
evidence of anti-tumor activity.
LAYN Reports Q3 revenue of $216.5 mln, down from $281.3 mln in
the year ago quarter and below the analyst consensus of $244.6 mln
on Capital IQ. Pre-tax loss was $0.99, vs. year ago income of $0.38
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.